Tempus AI Inc
TEM66.270USD
-2.090-3.06%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
11.78BMarket Cap
LossP/E TTM
More Details of Tempus AI Inc Company
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
Tempus AI Inc Info
Ticker SymbolTEM
Company nameTempus AI Inc
IPO dateMay 30, 2025
CEOLefkofsky (Eric P)
Number of employees2400
Security typeOrdinary Share
Fiscal year-endMay 30
Address600 West Chicago Avenue
CityCHICAGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code60654
Phone18335144187
Websitehttps://investors.tempus.com/
Ticker SymbolTEM
IPO dateMay 30, 2025
CEOLefkofsky (Eric P)
Company Executives of Tempus AI Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Ryan Fukushima
Mr. Ryan Fukushima
Chief Operating Officer
Chief Operating Officer
752.09K
-135234.00%
Mr. Peter J. Barris
Mr. Peter J. Barris
Independent Director
Independent Director
102.70K
-1322.00%
Mr. Eric D. Belcher
Mr. Eric D. Belcher
Independent Director
Independent Director
14.71K
-1997.00%
Mr. Andrew (Andy) Polovin
Mr. Andrew (Andy) Polovin
Executive Vice President, General Counsel, Company Secretary
Executive Vice President, General Counsel, Company Secretary
10.43K
-2447.00%
Mr. James (Jim) Rogers
Mr. James (Jim) Rogers
Chief Financial Officer
Chief Financial Officer
5.48K
-17168.00%
Mr. David R. Epstein
Mr. David R. Epstein
Independent Director
Independent Director
3.61K
-250.00%
Dr. Scott Gottlieb, M.D.
Dr. Scott Gottlieb, M.D.
Independent Director
Independent Director
1.25K
-1997.00%
Mr. Eric P. Lefkofsky, J.D.
Mr. Eric P. Lefkofsky, J.D.
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Mr. Erik J. Phelps, J.D.
Mr. Erik J. Phelps, J.D.
Executive Vice President, Chief Administrative and Legal Officer, Assistant Secretary
Executive Vice President, Chief Administrative and Legal Officer, Assistant Secretary
--
--
Dr. Jennifer A. Doudna, Ph.D.
Dr. Jennifer A. Doudna, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Ryan Fukushima
Mr. Ryan Fukushima
Chief Operating Officer
Chief Operating Officer
752.09K
-135234.00%
Mr. Peter J. Barris
Mr. Peter J. Barris
Independent Director
Independent Director
102.70K
-1322.00%
Mr. Eric D. Belcher
Mr. Eric D. Belcher
Independent Director
Independent Director
14.71K
-1997.00%
Mr. Andrew (Andy) Polovin
Mr. Andrew (Andy) Polovin
Executive Vice President, General Counsel, Company Secretary
Executive Vice President, General Counsel, Company Secretary
10.43K
-2447.00%
Mr. James (Jim) Rogers
Mr. James (Jim) Rogers
Chief Financial Officer
Chief Financial Officer
5.48K
-17168.00%
Mr. David R. Epstein
Mr. David R. Epstein
Independent Director
Independent Director
3.61K
-250.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Blue Media, LLC
10.49%
BK TL21 LLC
8.80%
Lefkofsky (Eric Paul)
6.77%
Baillie Gifford & Co.
5.61%
The Vanguard Group, Inc.
5.45%
Other
62.88%
Shareholders
Shareholders
Proportion
Blue Media, LLC
10.49%
BK TL21 LLC
8.80%
Lefkofsky (Eric Paul)
6.77%
Baillie Gifford & Co.
5.61%
The Vanguard Group, Inc.
5.45%
Other
62.88%
Shareholder Types
Shareholders
Proportion
Corporation
29.32%
Investment Advisor
28.43%
Investment Advisor/Hedge Fund
11.60%
Individual Investor
7.45%
Research Firm
5.19%
Hedge Fund
4.27%
Holding Company
3.13%
Venture Capital
0.91%
Bank and Trust
0.88%
Other
8.83%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
708
89.83M
51.96%
-1.45M
2025Q3
619
75.72M
43.81%
-4.20M
2025Q2
501
136.83M
81.41%
-3.18M
2025Q1
444
136.54M
81.24%
-3.30M
2024Q4
259
141.87M
89.45%
+26.80M
2024Q3
171
136.39M
89.94%
+26.38M
2024Q2
115
132.44M
88.72%
+132.44M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Blue Media, LLC
18.14M
10.49%
-7.69M
-29.78%
Aug 08, 2025
BK TL21 LLC
15.22M
8.8%
--
--
Mar 18, 2025
Lefkofsky (Eric Paul)
11.70M
6.77%
-16.83K
-0.14%
Nov 25, 2025
Baillie Gifford & Co.
9.69M
5.61%
-2.40M
-19.86%
Sep 30, 2025
The Vanguard Group, Inc.
9.42M
5.45%
+1.70M
+22.05%
Sep 30, 2025
Gray Media, LLC
9.27M
5.36%
-133.25K
-1.42%
Aug 08, 2025
Red Sky LLC
8.06M
4.66%
-1.44M
-15.13%
Sep 30, 2025
ARK Investment Management LLC
7.18M
4.15%
-246.00K
-3.31%
Sep 30, 2025
SoftBank Group Corp
5.41M
3.13%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
5.38M
3.11%
+2.26M
+72.19%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Genomic Revolution ETF
12.02%
ARK Innovation ETF
5.1%
Global X HealthTech ETF
4.22%
Franklin Genomic Advancements ETF
3.92%
Renaissance IPO ETF
3.83%
KraneShares Artificial Intelligence and Tcnlgy ETF
3.05%
AXS Green Alpha ETF
2.92%
ROBO Global Artificial Intelligence ETF
2.49%
First Trust Health Care Alphadex Fund
2.42%
Innovator IBD 50 Fund ETF
2.22%
View more
ARK Genomic Revolution ETF
Proportion12.02%
ARK Innovation ETF
Proportion5.1%
Global X HealthTech ETF
Proportion4.22%
Franklin Genomic Advancements ETF
Proportion3.92%
Renaissance IPO ETF
Proportion3.83%
KraneShares Artificial Intelligence and Tcnlgy ETF
Proportion3.05%
AXS Green Alpha ETF
Proportion2.92%
ROBO Global Artificial Intelligence ETF
Proportion2.49%
First Trust Health Care Alphadex Fund
Proportion2.42%
Innovator IBD 50 Fund ETF
Proportion2.22%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Tempus AI Inc?
The top five shareholders of Tempus AI Inc are:
Blue Media, LLC holds 18.14M shares, accounting for 10.49% of the total shares.
BK TL21 LLC holds 15.22M shares, accounting for 8.80% of the total shares.
Lefkofsky (Eric Paul) holds 11.70M shares, accounting for 6.77% of the total shares.
Baillie Gifford & Co. holds 9.69M shares, accounting for 5.61% of the total shares.
The Vanguard Group, Inc. holds 9.42M shares, accounting for 5.45% of the total shares.
Blue Media, LLC holds 18.14M shares, accounting for 10.49% of the total shares.
BK TL21 LLC holds 15.22M shares, accounting for 8.80% of the total shares.
Lefkofsky (Eric Paul) holds 11.70M shares, accounting for 6.77% of the total shares.
Baillie Gifford & Co. holds 9.69M shares, accounting for 5.61% of the total shares.
The Vanguard Group, Inc. holds 9.42M shares, accounting for 5.45% of the total shares.
What are the top three shareholder types of Tempus AI Inc?
The top three shareholder types of Tempus AI Inc are:
Blue Media, LLC
BK TL21 LLC
Lefkofsky (Eric Paul)
Blue Media, LLC
BK TL21 LLC
Lefkofsky (Eric Paul)
How many institutions hold shares of Tempus AI Inc (TEM)?
As of 2025Q4, 708 institutions hold shares of Tempus AI Inc, with a combined market value of approximately 89.83M, accounting for 51.96% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 8.16%.
What is the biggest source of revenue for Tempus AI Inc?
In --, the -- business generated the highest revenue for Tempus AI Inc, amounting to -- and accounting for --% of total revenue.
